Business Context and Reporting Period
This Form 8-K is a current report filed by Aileron Therapeutics, Inc. (not Rein Therapeutics, Inc.) on February 9, 2024. The filing addresses a specific executive compensation event approved by the Board of Directors on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
- Executive: Brian Windsor, Ph.D., President and Chief Operating Officer.
- Compensation Event: Performance-based cash bonus for the fiscal year ended December 31, 2023.
- Bonus Amount: $204,375.
- Updated Total Compensation (2023): $289,642.
Material Changes
This report updates the Summary Compensation Table previously disclosed in the Company's definitive proxy statement filed on January 29, 2024. The "Bonus" and "Total" columns for Dr. Windsor have been increased to reflect the newly approved cash bonus. No other named executive officers received a performance-based cash bonus for the 2023 fiscal year.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business operations, risk factors, contingencies, or unusual items beyond the specific compensation adjustment.
Investor Verification Checklist
- Verify the updated Summary Compensation Table in the 2023 proxy statement reflects the $204,375 bonus for Dr. Windsor.
- Confirm that no other named executive officers received performance-based bonuses for the 2023 fiscal year.
- Note the discrepancy between the requested company name (Rein Therapeutics) and the actual registrant (Aileron Therapeutics).